The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation

Biochemical and Biophysical Research Communications

Volumn 383, Issue 3, 2009, Pages 308-313

  Vu, Hoang Anh ^a,b   Xinh, Phan Thi ^b   Kano, Yasuhiko ^d   Tokunaga, Katsushi ^c   Sato, Yuko ^b  

^a WASEDA UNIVERSITY   (Japan)

^b Research Institute   (Japan)

^c GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

Author keywords

AKT; ETV6 FLT3; MAPK; PIM 1; STAT5

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; TRANSCRIPTION FACTOR ETV6;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; JUXTAMEMBRANE DOMAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS C-PIM-1; REPRESSOR PROTEINS; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 67349203576     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.03.157     Document Type: Article

References (24)

1. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., and Lemischka I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 88 (1991) 9026-9030
2. Rosnet O., Marchetto S., deLapeyriere O., and Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 6 (1991) 1641-1650
3. Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C., Toiron Y., Birg F., and Birnbaum D. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82 (1993) 1110-1119
4. Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S., and Ronnstrand L. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 108 (2006) 1542-1550
5. Tomasson M.H., Sternberg D.W., Williams I.R., Carroll M., Cain D., Aster J.C., Ilaria Jr. R.L., Van Etten R.A., and Gilliland D.G. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J. Clin. Invest. 105 (2000) 423-432
6. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
7. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., and Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
8. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., Goldstone A.H., and Linch D.C. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
9. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., Loffler H., Sauerland C.M., Serve H., Buchner T., Haferlach T., and Hiddemann W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
10. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A., Ehninger G., and Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
11. Reindl C., Bagrintseva K., Vempati S., Schnittger S., Ellwart J.W., Wenig K., Hopfner K.P., Hiddemann W., and Spiekermann K. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107 (2006) 3700-3707
12. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., Fischer T., Berdel W.E., Muller-Tidow C., and Serve H. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106 (2005) 265-273
13. Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P., and Gilliland D.G. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108 (2006) 1339-1345
14. Bagrintseva K., Geisenhof S., Kern R., Eichenlaub S., Reindl C., Ellwart J.W., Hiddemann W., and Spiekermann K. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 105 (2005) 3679-3685
15. Grundler R., Thiede C., Miething C., Steudel C., Peschel C., and Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 102 (2003) 646-651
16. Choudhary C., Muller-Tidow C., Berdel W.E., and Serve H. Signal transduction of oncogenic Flt3. Int. J. Hematol. 82 (2005) 93-99
17. Vu H.A., Xinh P.T., Masuda M., Motoji T., Toyoda A., Sakaki Y., Tokunaga K., and Sato Y. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 20 (2006) 1414-1421
18. Benekli M., Baer M.R., Baumann H., and Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101 (2003) 2940-2954
19. Murata K., Kumagai H., Kawashima T., Tamitsu K., Irie M., Nakajima H., Suzu S., Shibuya M., Kamihira S., Nosaka T., Asano S., and Kitamura T. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J. Biol. Chem. 278 (2003) 32892-32898
20. Kiyoi H., Ohno R., Ueda R., Saito H., and Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21 (2002) 2555-2563
21. Kim K.T., Baird K., Ahn J.Y., Meltzer P., Lilly M., Levis M., and Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105 (2005) 1759-1767
22. Kim K.T., Levis M., and Small D. Constitutively activated FLT3 phosphorylates BAD partially through Pim-1. Br. J. Haematol. 134 (2009) 500-509
23. Wernig G., Gonneville J.R., Crowley B.J., Rodrigues M.S., Reddy M.M., Hudon H.E., Walz C., Reiter A., Podar K., Royer Y., Constantinescu S.N., Tomasson M.H., Griffin J.D., Gilliland D.G., and Sattler M. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111 (2008) 3751-3759
24. Krumenacker J.S., Narang V.S., Buckley D.J., and Buckley A.R. Prolactin signaling to pim-1 expression: a role for phosphatidylinositol 3-kinase. J. Neuroimmunol. 113 (2001) 249-259